These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 27088859

  • 1. Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.
    Bertocchio JP, Barbe C, Lavaud S, Toupance O, Nazeyrollas P, Jaisser F, Rieu P.
    PLoS One; 2016; 11(4):e0153635. PubMed ID: 27088859
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 3. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F.
    Circ Heart Fail; 2014 Jan 22; 7(1):51-8. PubMed ID: 24297687
    [Abstract] [Full Text] [Related]

  • 4. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, Tyrwhitt J, Bosch J, Gao P, Devereaux PJ, Wald R.
    Clin J Am Soc Nephrol; 2015 Sep 04; 10(9):1602-8. PubMed ID: 26138259
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases.
    Pavleska-Kuzmanovska S, Popov Z, Ivanovski O, Ristovska V, Masin-Spasovska J, Rambabova-Busljetic I, Ivanovski N.
    Exp Clin Transplant; 2014 Oct 04; 12(5):479-83. PubMed ID: 24417207
    [Abstract] [Full Text] [Related]

  • 6. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C.
    Int J Cardiol; 2015 Dec 01; 200():25-9. PubMed ID: 26404748
    [Abstract] [Full Text] [Related]

  • 7. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 8. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP.
    Expert Opin Pharmacother; 2008 Mar 15; 9(4):509-15. PubMed ID: 18312153
    [Abstract] [Full Text] [Related]

  • 9. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 10. Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients.
    Sakallı H, Baskın E, Bayrakcı US, Moray G, Haberal M.
    Exp Clin Transplant; 2014 Aug 14; 12(4):310-3. PubMed ID: 24447308
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.
    Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K.
    Clin Transplant; 2004 Apr 14; 18(2):186-92. PubMed ID: 15016134
    [Abstract] [Full Text] [Related]

  • 12. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
    Medeiros M, Velásquez-Jones L, Hernández AM, Ramón-García G, Valverde S, Fuentes Y, Vargas A, Patiño M, Pérez-Villalva R, Ortega-Trejo JA, Barrera-Chimal J, Bobadilla NA.
    Clin J Am Soc Nephrol; 2017 Aug 07; 12(8):1291-1300. PubMed ID: 28536123
    [Abstract] [Full Text] [Related]

  • 13. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
    Cai L, Zeng F, Liu B, Wei L, Chen Z, Jiang J.
    Int J Clin Pract Suppl; 2014 Apr 07; (181):23-30. PubMed ID: 24673716
    [Abstract] [Full Text] [Related]

  • 14. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, EVALUATE Study Group.
    Lancet Diabetes Endocrinol; 2014 Dec 07; 2(12):944-53. PubMed ID: 25466242
    [Abstract] [Full Text] [Related]

  • 15. [Metabolic disorders in renal transplant recipients].
    Mikolasević I, Jelić I, Sladoje-Martinović B, Orlić L, Zivcić-Cosić S, Vuksanović-Mikulicić S, Mijić M, Racki S.
    Acta Med Croatica; 2012 Jul 07; 66(3):235-41. PubMed ID: 23441539
    [Abstract] [Full Text] [Related]

  • 16. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.
    Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P.
    BMC Nephrol; 2013 Feb 20; 14():42. PubMed ID: 23425330
    [Abstract] [Full Text] [Related]

  • 17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ.
    Int J Cardiol; 2015 Dec 01; 200():15-9. PubMed ID: 26404747
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
    Sun QL, Li M, Rui HL, Chen YP.
    J Renin Angiotensin Aldosterone Syst; 2015 Jun 01; 16(2):301-10. PubMed ID: 25500744
    [Abstract] [Full Text] [Related]

  • 19. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM, Pelliccia F, Zivkovic I, Ristic A, Lalic N, Seferovic J, Simeunovic D, Milinkovic I, Rosano G.
    Int J Cardiol; 2015 Dec 01; 200():3-7. PubMed ID: 26404746
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R.
    Hypertension; 2009 May 01; 53(5):754-60. PubMed ID: 19307466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.